This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

Professionals 232 Users Online

Pneumatic Nebulizers Market

Market Study on Pneumatic Nebulizers: Surge in incidences of Asthma and COPD t trigger the Demand for Pneumatic Nebulizers

Pneumatic Nebulizers Market by Product Type (Breath-actuated and Vented)

Pneumatic Nebulizers Market Outlook (2022-2032)

The Pneumatic Nebulizers market was valued at around US$ 726.9 Mn in 2021. With a projected CAGR of 7.1% for the next ten years, the market is likely to reach a valuation of nearly US$ 1.5 Bn by the end of 2032. The market is expected to register an absolute dollar opportunity of 760 Mn during the forecast period. The increasing number of cases of asthma, and COPD over the years have been advantageous for the demand for Pneumatic Nebulizers.

Attributes

Details

Pneumatic Nebulizers Market Size (2022E)

US$ 776.2 Mn

Projected Market Value (2032F)

US$ 1.5 Bn

Global Market Growth Rate (2022-2032)

7.1% CAGR

North America Market Share (2021)

>30%

Key Companies Profiled

  • Koninklijke Philips N.V.
  • Omron Corporation
  • General Electric
  • Medline Industries Inc.
  • BD (Becton, Dickinson & Company)
  • Allied Healthcare Products
  • Philips Respironics Inc.
  • Briggs Healthcare
  • Heyer Medical AG
  • Medtronic PLC
  • PARI Pharma GmbH
  • Airssential Health Care
  • Vectura Group Plc
  • DeVilbiss Healthcare
  • Flexicare Medical Ltd.
  • Clement Clarke International
Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of Pneumatic Nebulizers from 2017 to 2021 Vs Market Outlook for 2022 to 2032

The global market for Pneumatic Nebulizers expanded at a CAGR of 6.4% during 2017-2021. The market growth is projected to be augmented by the expedited requirement of Breath-actuated Pneumatic Nebulizers in the forthcoming years. The global Pneumatic Nebulizers market is predicted to surge ahead at a CAGR of 7.1% and record sales worth US$ 1.5 Bn by the end of 2032. US will continue to be the largest market throughout the analysis period accounting for over US$ 212 Mn absolute dollar opportunity in the coming 10-year epoch.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

Which factors are propelling the Global Pneumatic Nebulizers Market?

Among the various factors advantageous to the growth of the Global Pneumatic Nebulizers Market during the upcoming 10-year epoch, the key attribute is the accelerated rise in the cases of various respiratory disorders around the world, including asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD) to name a few. Taking into account the recent WHO (World Health Organization) report published in May 2022, Chronic Obstructive Pulmonary Disease (COPD) is the third most prominent reason of death around the globe, contributing to as many as 3.23 Mn deaths in 2019.

Data from the same report further throw light on the fact that approximately 262 Mn people were suffering from Asthma as of 2019. This cohort of patients is estimated to further expand during the forecast period, and subsequently help the growth of the Global Pneumatic Nebulizers Market. Additionally, the growth of the Global Pneumatic Nebulizers Market is further aided by the cost-efficiency and the ease of operability associated with the Pneumatic Nebulizers relative to other Nebulizers available in the market. Furthermore, third parties paying on the behalf of patients, like insurance-providing firms, tend to be more inclined toward the use of pneumatic nebulizers which is subsequently aided by their cost-effectiveness whilst still being able to provide state-of-the-art medical services.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Region-wise Insights

Why does Asia-Pacific Stand as the Most Lucrative Market for Pneumatic Nebulizers Market?

In the forthcoming years, the Asia-Pacific region is anticipated to be highly lucrative for the Pneumatic Nebulizers Market. A 2018 study brought to light the fact that around 8.6% of the total adult population of China, as many as 100 Mn people, suffers from Chronic Obstructive Pulmonary Disease (COPD). This can be among the attributes associated with the growth of the Pneumatic Nebulizers Market in China, which is projected for a CAGR of 7.6% to witness an absolute dollar opportunity of US$ 92 Mn and reach the total market valuation of US$ 176.9 Mn by 2032.

Taking into account the recent data issued by the WHO (World Health Organization) in 2020, deaths related to lung diseases in Japan have accounted for 7.08% of the total deaths in the country. It has been further noted that of the 93 Mn chronic respiratory conditions cases in India, 37 Mn are due to Asthma. Additionally, the country makes up for 11.1% of the global asthma burden, accounting for more than 42% of related deaths, thereby making the nation, the asthma capital of the world. All these factors are forecasted to work in the favor of the growth of the Pneumatic Nebulizers Market in the Asia-Pacific region in the upcoming 10-year forecast epoch.

How is the Pneumatic Nebulizers Market in North America Shaping Up?

With a market share of more than 30% in the Global Pneumatic Nebulizers Market, North American is expected to maintain its dominant position intact during the forthcoming years. The increasing cohort of people with Chronic Obstructive Pulmonary Disease (COPD), Asthma, and other related respiratory disorders is anticipated to be advantageous to the Pneumatic Nebulizers Market in the North American region. In Canada, 10.8% of the total population suffers from Asthma with the disease affecting as many as 3.8 Mn people, as mentioned in the 2018 report of The Canadian Chronic Disease Surveillance System. The report further accounted for over 2 Mn patients of Chronic Obstructive Pulmonary Disease (COPD) in the nation.

A 2018 article published in the American Thoracic Society reported that asthma costs approximately more than US$ 80 Bn to the U.S. economy. These attributes are estimated to be among the driving factors beneficial for the Pneumatic Nebulizers Market in the North American region during the upcoming 10-year epoch.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

U.S. Pneumatic Nebulizers Market Analysis

The Global Pneumatic Nebulizers Market in the U.S. is forecasted to experience a CAGR of 6.8% and an absolute dollar opportunity of US$ 212 Mn to reach a total market valuation of US$ 439.5 Mn by the end of 2032. In April 2017, the U.S. FDA (Food and Drug Administration) approved the VOCSN device manufactured by Ventec Life Systems by giving it 510(k) clearance, which is anticipated to be beneficial for the Pneumatic Nebulizers Market during the forecast period.

Taking into account the recent data from the Centers for Disease Control and Prevention (CDC), as of 2020, there are as many as 25.3 Mn people, or approximately 7.8% of the population in the country that suffer from Asthma. A 2021 American Lung Association report is of the opinion that Chronic Obstructive Pulmonary Disease (COPD) is the third major source of death by disease in the U.S. As of 2021, there are more than 16.4 Mn patients with COPD in the U.S., the same report stated. As per an article published by the National Institutes of Health (NIH) in the National Library of Medicine, the direct costs associated with Chronic Obstructive Pulmonary Disease (COPD) amount to US$ 50 Bn annually. All these factors are anticipated to be advantageous towards the expansion of the Global Pneumatic Nebulizers Demand in the U.S. in the forthcoming years.

U.K. Pneumatic Nebulizers Market Analysis

The market in the U.K. is projected to reach a valuation of US$ 80 Mn by 2032. With a projected CAGR of 7.4%, the market is expected to register an absolute dollar opportunity of US$ 41 Mn during 2022 – 2032.

Japan Pneumatic Nebulizers Market Analysis

The Japanese market is expected to grow at a CAGR of 6.9% during 2022 – 2032 to reach a valuation of US$ 60 Mn by 2032. The market is expected to register an absolute dollar opportunity of US$ 29 Mn during the forecast period.

South Korea Pneumatic Nebulizers Market Analysis

In South Korea, the market increased at a CAGR of 7% during 2017 – 2021 to reach a valuation of around US$ 40 Mn by 2032. With a projected CAGR of 7.7%, the market is expected to gross an absolute dollar opportunity of US$ 20.7 Mn during 2022 – 2032.

Category-wise Insights

How has the Increasing Use of Breath-actuated Pneumatic Nebulizers impacted the Pneumatic Nebulizers Market?

The Breath-actuated Nebulizers in the Pneumatic Nebulizers Market are forecasted to grow at a CAGR of 6.9% during the 10-year forecasted epoch. This growth can be attributed to the involved greater drug delivery capacity relative to the Vented Nebulizers and the lesser wastage of the dose to be administered. The increasing cohort of people suffering from Chronic Obstructive Pulmonary Diseases (COPD) across the globe is anticipated to be advantageous to the Pneumatic Nebulizers Market during the upcoming 10-year epoch.

In recent years, nebulizers have emerged as a better and more efficient alternative to inhalers in the most common, inhalation therapy treatment for Chronic Obstructive Pulmonary Disease (COPD). It is due to their ability to deliver a continuous medication mist, particularly breath-actuated nebulizers. A development that has been of advantage to the key market players in the Pneumatic Nebulizers industry. With organizations like the WHO (World Health Organization) predicting a consistent increase in the cohort of the population around the world suffering from Chronic Obstructive Pulmonary Disease (COPD), the breath-actuated nebulizers are projected to positively impact the Pneumatic Nebulizers Market during the forthcoming forecast years.

How are Pneumatic Nebulizers Demand Expected to Perform with their Growing Necessity in Hospitals & Clinics?

The market revenue through Hospitals & Clinics is expected to witness a CAGR of 7.1% by the end of 2032. An article published in the Annals of Translational Medicine in 2019, brought to light the extensive benefits of nebulizers, especially pneumatic nebulizers, relative to alternative inhalation therapies available. Among other beneficial attributes, is its safety profile which makes it a favored choice among any and all patients, including those on mechanical ventilation along with children and the elderly cohort. The average cost of a Pneumatic Nebulizer in India is US$ 22.5 making it all the more advantageous in comparison to an ultrasonic nebulizer which cost around US$ 90.8 based on cost-effectiveness. These factors are expected to positively impact the revenue growth through the Hospitals & Clinics during the forthcoming forecast years.

Competitive Analysis

Koninklijke Philips N.V., Omron Corporation, General Electric, Medline Industries Inc., BD (Becton, Dickinson & Company), Allied Healthcare Products, Philips Respironics Inc., Briggs Healthcare, Heyer Medical AG, Medtronic PLC, PARI Pharma GmbH, Airssential Health Care, Vectura Group Plc., DeVilbiss Healthcare, Flexicare Medical Ltd., and, Clement Clarke International are among the key players worldwide driving the competitive landscape of the market. To expand their product portfolio and simultaneously capitalize on the growing market demand, many of these companies are adopting strategies such as mergers, acquisitions, and partnerships. Key market players shaping the Pneumatic Nebulizers Industry are also focused on new product launches to expand their brand value and product portfolio in the Global Pneumatic Nebulizers during the upcoming 10-year epoch.

Some of the key recent developments in the pneumatic nebulizers market include:

  • In June 2021, Vectura Group Plc completed a buy-out of Skeypharma Production SAS, an oral manufacturing subsidiary based in Lyon, France. This announcement highlights the 2019 aim of the Vectura Group in order to become a completely inhalation focussed CDMO. This decision is set to positively impact Vectura Group Plc. during the upcoming forecast period.
  • In March 2021, the authorization of PARI Pharma GmbH’s LAMIRA Nebulizer System in Japan was announced. The nebulizing system has been announced to deliver ARIKAYCE (amikacin liposome inhalation suspension) developed by Insmed.
  • In January 2020, a new Automation Center in Tokyo was announced by OMRON Corporation, in order to enable customers to be included with the company for finding solutions to any challenges that may arise during the manufacturing process.

Key Segments Covered in Market Survey

By Product-type

  • Breath-actuated
  • Vented

By End-use

  • Hospitals & Clinics
  • Home Healthcare

By Region

  • North America
    • The US
    • Canada
  • The Asia Pacific
    • China
    • Japan
    • South Korea
    • India
  • Europe
    • Germany
    • The UK
    • France
    • Russia
    • Italy
  • The Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Nigeria
    • Egypt
  • Latin America
    • Mexico
    • Brazil
    • Argentina
    • Colombia

- Companies Covered in This Report -

  • Koninklijke Philips N.V.
  • Omron Corporation
  • General Electric
  • Medline Industries Inc.
  • Becton, Dickinson & Company
  • Allied Healthcare Products
  • Philips Respironics Inc.
  • Briggs Healthcare
  • Heyer Medical AG
  • Medtronic PLC
  • PARI Pharma GmbH
  • Airssential Health Care
  • Vectura Group Plc
  • DeVilbiss Healthcare
  • Flexicare Medical Ltd.
  • Clement Clarke International

- Frequently Asked Questions -

The Pneumatic Nebulizers market was valued at US$ 726.9 Mn in 2021.

The Pneumatic Nebulizers industry is set to witness a growth rate of 7.1% over the forecast period and be valued at US$ 1.5 Bn by 2032.

Koninklijke Philips N.V., Omron Corporation, General Electric, Medline Industries Inc., BD (Becton, Dickinson & Company), Allied Healthcare Products, Philips Respironics Inc., Briggs Healthcare, Heyer Medical AG, Medtronic PLC, PARI Pharma GmbH, Airssential Health Care, Vectura Group Plc., DeVilbiss Healthcare, Flexicare Medical Ltd., and, Clement Clarke International are among the key players shaping up the Pneumatic Nebulizers Industry.

The preference for breath-actuated pneumatic nebulizers is consistently increasing and is anticipated to favorably impact the global demand for pneumatic nebulizers over the forecast period till 2032.

The market in the US is expected to reach a valuation of US$ 439.5 Mn during the forecast period along with a CAGR of 6.8%.

The Asia Pacific market is expected to grow significantly during the forecast period mainly due to, rising cases of Asthma and COPD, especially in developing economies such as India.

Google translate